{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:27:51Z","timestamp":1790728071445,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270703"],"award-info":[{"award-number":["82270703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970606"],"award-info":[{"award-number":["81970606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970595"],"award-info":[{"award-number":["81970595"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2020YFC2005000"],"award-info":[{"award-number":["2020YFC2005000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022JKXYD03001"],"award-info":[{"award-number":["2022JKXYD03001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&amp;D Program of China","award":["82270703"],"award-info":[{"award-number":["82270703"]}]},{"name":"National Key R&amp;D Program of China","award":["81970606"],"award-info":[{"award-number":["81970606"]}]},{"name":"National Key R&amp;D Program of China","award":["81970595"],"award-info":[{"award-number":["81970595"]}]},{"name":"National Key R&amp;D Program of China","award":["2020YFC2005000"],"award-info":[{"award-number":["2020YFC2005000"]}]},{"name":"National Key R&amp;D Program of China","award":["2022JKXYD03001"],"award-info":[{"award-number":["2022JKXYD03001"]}]},{"name":"East China Normal University Medicine and Health Joint Fund","award":["82270703"],"award-info":[{"award-number":["82270703"]}]},{"name":"East China Normal University Medicine and Health Joint Fund","award":["81970606"],"award-info":[{"award-number":["81970606"]}]},{"name":"East China Normal University Medicine and Health Joint Fund","award":["81970595"],"award-info":[{"award-number":["81970595"]}]},{"name":"East China Normal University Medicine and Health Joint Fund","award":["2020YFC2005000"],"award-info":[{"award-number":["2020YFC2005000"]}]},{"name":"East China Normal University Medicine and Health Joint Fund","award":["2022JKXYD03001"],"award-info":[{"award-number":["2022JKXYD03001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Farnesoid X receptor, also known as the bile acid receptor, belongs to the nuclear receptor (NR) superfamily of ligand-regulated transcription factors, which performs its functions by regulating the transcription of target genes. FXR is highly expressed in the liver, small intestine, kidney and adrenal gland, maintaining homeostasis of bile acid, glucose and lipids by regulating a diverse array of target genes. It also participates in several pathophysiological processes, such as inflammation, immune responses and fibrosis. The kidney is a key organ that manages water and solute homeostasis for the whole body, and kidney injury or dysfunction is associated with high morbidity and mortality. In the kidney, FXR plays an important role in renal water reabsorption and is thought to perform protective functions in acute kidney disease and chronic kidney disease, especially diabetic kidney disease. In this review, we summarize the recent advances in the understanding of the physiological and pathophysiological function of FXR in the kidney.<\/jats:p>","DOI":"10.3390\/ijms24032408","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T02:29:31Z","timestamp":1674700171000},"page":"2408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Role of FXR in Renal Physiology and Kidney Diseases"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4422-3954","authenticated-orcid":false,"given":"Yanlin","family":"Guo","sequence":"first","affiliation":[{"name":"Health Science Center, East China Normal University, Shanghai 200241, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University, Shanghai 200241, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-2423","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Science Center, East China Normal University, Shanghai 200241, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.addr.2010.07.002","article-title":"Nuclear receptors as drug targets for metabolic disease","volume":"62","author":"Schulman","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_2","first-page":"72","article-title":"Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors","volume":"9","author":"Seol","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Boesjes, M., Bloks, V.W., Hageman, J., Bos, T., van Dijk, T.H., Havinga, R., Wolters, H., Jonker, J.W., Kuipers, F., and Groen, A.K. (2014). Hepatic Farnesoid X-Receptor Isoforms \u03b12 and \u03b14 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115028"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/molbev\/msm251","article-title":"Analysis of Nuclear Receptor Pseudogenes in Vertebrates: How the Silent Tell Their Stories","volume":"25","author":"Zhang","year":"2007","journal-title":"Mol. Biol. Evol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108893","DOI":"10.1016\/j.abb.2021.108893","article-title":"Identification and characterization of novel splice variants of human farnesoid X receptor","volume":"705","author":"Mustonen","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/MCB.23.3.864-872.2003","article-title":"Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol","volume":"23","author":"Otte","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI68815","article-title":"Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk","volume":"124","author":"Lien","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e001","DOI":"10.1621\/nrs.10001","article-title":"Post-Translational Modifications of Nuclear Receptors and Human Disease","volume":"10","author":"Anbalagan","year":"2012","journal-title":"Nucl. Recept. Signal."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1101\/gad.1138104","article-title":"Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR","volume":"18","author":"Zhang","year":"2004","journal-title":"Genes Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/me.2008-0092","article-title":"Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity","volume":"22","author":"Gineste","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/hep.26710","article-title":"Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR)","volume":"59","author":"Berrabah","year":"2014","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","article-title":"FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States","volume":"10","author":"Kemper","year":"2009","journal-title":"Cell Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"36863","DOI":"10.1074\/jbc.R100047200","article-title":"Nuclear Receptor Minireview Series","volume":"276","author":"Olefsky","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kenakin, T. (2022). Comprehensive Pharmacology, Elsevier.","DOI":"10.1016\/B978-0-323-99289-3.00017-8"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nsb0196-87","article-title":"A canonical structure for the ligand-binding domain of nuclear receptors","volume":"3","author":"Wurtz","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: A structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1074\/jbc.275.14.10638","article-title":"Identification of the DNA Binding Specificity and Potential Target Genes for the Farnesoid X-activated Receptor","volume":"275","author":"Laffitte","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.1016\/S0168-8278(18)31427-2","article-title":"Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects","volume":"68","author":"Ahmad","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1021\/ci300459k","article-title":"Unbinding Pathways of GW4064 from Human Farnesoid X Receptor as Revealed by Molecular Dynamics Simulations","volume":"52","author":"Li","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients with Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non\u2013bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Marotta, C., Ahmad, A., Luo, E., Oosterhaven, J., van Marle, S., and Adda, N. (2022). EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects. Clin. Transl. Sci., in press.","DOI":"10.1111\/cts.13453"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","article-title":"An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers","volume":"155","author":"Rudling","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2020","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study","volume":"28","author":"Erken","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR Ligands: Current Status and Clinical Applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb. Exp. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Brevini, T., Maes, M., Webb, G.J., John, B.V., Fuchs, C.D., Buescher, G., Wang, L., Griffiths, C., Brown, M.L., and Scott, W.E. (2022). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature, in press.","DOI":"10.1038\/s41586-022-05594-0"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-020-01399-5","article-title":"A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis","volume":"20","author":"Nakano","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hill, A., and Mirchandani, M. (2022). The dangers of non-randomized, observational studies: Experience from the COVID-19 epidemic. J. Antimicrob. Chemother., in press.","DOI":"10.1093\/jac\/dkac437"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Naggie, S., Boulware, D.R., Lindsell, C.J., Stewart, T.G., Lim, S.C., Cohen, J., Kavtaradze, D., Amon, A.P., Gabriel, A., and Gentile, N. (2022). Effect of Ivermectin 600 \u03bcg\/kg for 6 days vs. Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. medRxiv.","DOI":"10.1101\/2022.12.15.22283488"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1016\/j.bmc.2015.08.021","article-title":"Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists","volume":"23","author":"Song","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/15622975.2010.527370","article-title":"Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation","volume":"12","author":"Kreinin","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted Disruption of the Nuclear Receptor FXR\/BAR Impairs Bile Acid and Lipid Homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The Orphan Nuclear Receptor, shp, Mediates Bile Acid-Induced Inhibition of the Rat Bile Acid Transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M109326200","article-title":"Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor","volume":"277","author":"Kast","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1074\/jbc.M011610200","article-title":"Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor\/Bile Acid Receptor","volume":"276","author":"Ananthanarayanan","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_54","first-page":"G1124","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST\u03b1-OST\u03b2 in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"19909","DOI":"10.1074\/jbc.M207903200","article-title":"Liver Receptor Homologue-1 Mediates Species- and Cell Line-specific Bile Acid-dependent Negative Feedback Regulation of the Apical Sodium-dependent Bile Acid Transporter","volume":"278","author":"Chen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","article-title":"Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer","volume":"274","author":"Grober","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-\u03b1 and-\u03b2 genes","volume":"290","author":"Landrier","year":"2006","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.phymed.2018.09.006","article-title":"Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor","volume":"53","author":"Dong","year":"2018","journal-title":"Phytomedicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/MCB.01004-12","article-title":"Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes","volume":"33","author":"Caron","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154771","DOI":"10.1016\/j.metabol.2021.154771","article-title":"Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist","volume":"119","author":"Zhao","year":"2021","journal-title":"Metabolism"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1172\/JCI65538","article-title":"Hepatic glucose sensing is required to preserve \u03b2 cell glucose competence","volume":"123","author":"Seyer","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbadis.2010.01.002","article-title":"The bile acid sensor FXR regulates insulin transcription and secretion","volume":"1802","author":"Renga","year":"2010","journal-title":"Biochim. et Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_65","first-page":"1","article-title":"FXR Mediates Adenylyl Cyclase 8 Expression in Pancreatic \u03b2-Cells","volume":"2019","author":"Kong","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2019.08.009","article-title":"Roux-en-Y gastric bypass enhances insulin secretion in type 2 diabetes via FXR-mediated TRPA1 expression","volume":"29","author":"Kong","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1074\/jbc.M206749200","article-title":"Bile Acids Enhance Low Density Lipoprotein Receptor Gene Expression via a MAPK Cascade-mediated Stabilization of mRNA","volume":"277","author":"Nakahara","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes","volume":"582","author":"Langhi","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1074\/jbc.M209525200","article-title":"The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis","volume":"278","author":"Lambert","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","article-title":"Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling\u2013activated Src maintains cholesterol levels and protects from atherosclerosis","volume":"294","author":"Byun","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lai, C.-R., Tsai, Y.-L., Tsai, W.-C., Chen, T.-M., Chang, H.-H., Changchien, C.-Y., Wu, S.-T., Wang, H.-H., Chen, Y., and Lin, Y.-H. (2022). Farnesoid X Receptor Overexpression Decreases the Migration, Invasion and Angiogenesis of Human Bladder Cancers via AMPK Activation and Cholesterol Biosynthesis Inhibition. Cancers, 14.","DOI":"10.3390\/cancers14184398"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e14387","DOI":"10.14814\/phy2.14387","article-title":"FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet","volume":"8","author":"Singh","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity","volume":"29","author":"Wang","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13476","DOI":"10.1111\/jfbc.13476","article-title":"Trans-Chalcone inhibits high-fat diet-induced disturbances in FXR\/SREBP-1c\/FAS and FXR\/Smad-3 pathways in the kidney of rats","volume":"44","author":"Alipour","year":"2020","journal-title":"J. Food Biochem."},{"key":"ref_76","first-page":"1723","article-title":"Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db\/db mice","volume":"42","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.kint.2022.01.029","article-title":"Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation","volume":"101","author":"Xu","year":"2022","journal-title":"Kidney Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","article-title":"Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance","volume":"30","author":"Ma","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zhou, W., Bandara, S.R., Leal, C., and Anakk, S. (2021). Lipid droplet structural remodeling in adipose tissue upon caloric excess. bioRxiv.","DOI":"10.1101\/2021.08.23.457409"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2020.04.075","article-title":"Promotion of lipogenesis by PPAR\u03b3-activated FXR expression in adipocytes","volume":"527","author":"Shinohara","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1194\/jlr.M094508","article-title":"FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements [S]","volume":"60","author":"Stroeve","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_82","first-page":"159257","article-title":"Role of bile acid receptor FXR in development and function of brown adipose tissue","volume":"1868","author":"Yang","year":"2023","journal-title":"Biochim. et Biophys. Acta (BBA)\u2014Mol. Cell Biol. Lipids"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e22583","DOI":"10.1096\/fj.202200856R","article-title":"Genetic deletion of the nuclear factor of activated T cells 5 in collecting duct principal cells causes nephrogenic diabetes insipidus","volume":"36","author":"Petrillo","year":"2022","journal-title":"FASEB J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1073\/pnas.1323977111","article-title":"Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00424-020-02456-4","article-title":"Activation of farnesoid X receptor (FXR) induces crystallin zeta expression in mouse medullary collecting duct cells.","volume":"472","author":"Alam","year":"2020","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1073\/pnas.1803945115","article-title":"Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress","volume":"115","author":"Xu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2016101095","article-title":"Hepatocyte Nuclear Factor\u20131\u03b2 Regulates Urinary Concentration and Response to Hypertonicity","volume":"28","author":"Aboudehen","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(03)00228-9","article-title":"Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine","volume":"39","author":"Zollner","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1194\/jlr.M500427-JLR200","article-title":"Fxr(-\/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids","volume":"47","author":"Marschall","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","article-title":"Coordinated induction of bile acid detoxification and alternative elimination in mice: Role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids","volume":"290","author":"Zollner","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/mp0499656","article-title":"Regulation of Drug Transporters by the Farnesoid X Receptor in Mice","volume":"1","author":"Maeda","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/HJH.0000000000003189","article-title":"Renal Farnesoid X Receptor improves high fructose-induced salt-sensitive hypertension in mice by inhibiting DNM3 to promote nitro oxide production","volume":"40","author":"Zhu","year":"2022","journal-title":"J. Hypertens."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jash.2015.04.006","article-title":"Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats","volume":"9","author":"Li","year":"2015","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ghebremariam, Y.T., Yamada, K., Lee, J.C., Johnson, C.L.C., Atzler, D., Anderssohn, M., Agrawal, R., Higgins, J.P., Patterson, A.J., and B\u00f6ger, R.H. (2013). FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl Rats. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060653"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1700001","DOI":"10.1002\/pmic.201700001","article-title":"Quantitative Proteomics and Targeted Fatty Acids Analysis Reveal the Damage of Triptolide in Liver and Kidney","volume":"17","author":"Li","year":"2017","journal-title":"Proteomics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1038\/s41598-017-10168-6","article-title":"Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage","volume":"7","author":"Gai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-03620-z","article-title":"The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD","volume":"12","author":"Kim","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"F617","DOI":"10.1152\/ajprenal.00193.2021","article-title":"A naturally occurring FXR agonist, alisol B 23-acetate, protects against renal ischemia-reperfusion injury","volume":"321","author":"Luan","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e13005","DOI":"10.1111\/cpr.13005","article-title":"Farnesoid X receptor promotes renal ischaemia-reperfusion injury by inducing tubular epithelial cell apoptosis","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_100","first-page":"174","article-title":"Knockout of farnesoid X receptor gene aggravates cisplatin-induced kidney injury","volume":"47","author":"Zhang","year":"2022","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Bae, E.H., Choi, H.S., Joo, S.Y., Kim, I.J., Kim, C.S., Choi, J.S., Ma, S.K., Lee, J., and Kim, S.W. (2014). Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086553"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.redox.2022.102382","article-title":"Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes","volume":"54","author":"Kim","year":"2022","journal-title":"Redox Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2018.09.009","article-title":"Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury","volume":"838","author":"Zhu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tox.2017.01.007","article-title":"Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation","volume":"378","author":"Zhang","year":"2017","journal-title":"Toxicology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1053\/j.ajkd.2004.10.009","article-title":"Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States","volume":"45","author":"Collins","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_107","first-page":"2032","article-title":"Diabetic Kidney Disease","volume":"12","author":"Alicic","year":"2017","journal-title":"Chall. Prog. Possibilities"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2014121271","article-title":"G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes","volume":"27","author":"Wang","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00592-020-01652-z","article-title":"Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model","volume":"58","author":"Han","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1681\/ASN.2016101123","article-title":"Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy","volume":"28","author":"Marquardt","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.90585.2008","article-title":"A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia","volume":"296","author":"Evans","year":"2009","journal-title":"Am. J. Phys-iol.-Gastrointest. Liver Physiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mce.2015.10.001","article-title":"Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy","volume":"419","author":"Zhou","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.2337\/db10-0019","article-title":"Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model","volume":"59","author":"Wang","year":"2010","journal-title":"Diabetes"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-02170-5","article-title":"FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake","volume":"17","author":"Li","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"F1587","DOI":"10.1152\/ajprenal.00404.2009","article-title":"The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12986-015-0032-3","article-title":"FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity","volume":"12","author":"Glastras","year":"2015","journal-title":"Nutr. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000341485","article-title":"Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats","volume":"36","author":"Hu","year":"2012","journal-title":"Kidney Blood Press. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1074\/jbc.M115.694323","article-title":"Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice","volume":"291","author":"Gai","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"37234","DOI":"10.1038\/srep37234","article-title":"Activation of FXR protects against renal fibrosis via suppressing Smad3 expression","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1096\/fj.201900325R","article-title":"Src-mediated crosstalk between FXR and YAP protects against renal fibrosis","volume":"33","author":"Kim","year":"2019","journal-title":"FASEB J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1096\/fj.201801699R","article-title":"The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction","volume":"33","author":"Li","year":"2019","journal-title":"FASEB J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1042\/CS20200452","article-title":"Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2\u03b1-activated COX-TXA2 pathway","volume":"134","author":"Tsai","year":"2020","journal-title":"Clin. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Ratziu, V., Harrison, S.A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., and Darteil, R. (2022). Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2022.10.023"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Girisa, S., Shabnam, B., Monisha, J., Fan, L., Halim, C.E., Arfuso, F., Ahn, K.S., Sethi, G., and Kunnumakkara, A.B. (2019). Potential of Zerumbone as an Anti-Cancer Agent. Molecules, 24.","DOI":"10.3390\/molecules24040734"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2131\/jts.45.25","article-title":"Farnesoid X receptor and liver X receptors regulate Oct3\/4 expression by multiple feedback regulating system in normal renal-derived cells and renal adenocarcinoma cells","volume":"45","author":"Fujino","year":"2020","journal-title":"J. Toxicol. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/74199","article-title":"Quantitative expression of Oct-3\/4 defines differentiation, dedifferentiation or self-renewal of ES cells","volume":"24","author":"Niwa","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2015.02.105","article-title":"Oct3\/4 directly regulates expression of E2F3a in mouse embryonic stem cells","volume":"459","author":"Kanai","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_129","first-page":"5243","article-title":"Oct3\/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells","volume":"16","author":"Tomizawa","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2131\/jts.42.259","article-title":"Farnesoid X receptor regulates the growth of renal adenocarcinoma cells without affecting that of a normal renal cell-derived cell line","volume":"42","author":"Fujino","year":"2017","journal-title":"J. Toxicol. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-17755-2","article-title":"A multiomics disease progression signature of low-risk ccRCC","volume":"12","author":"Strauss","year":"2022","journal-title":"Sci. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:15:51Z","timestamp":1760120151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":131,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032408"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032408","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}